Dr. Imran Zoberi, MD

Dr. Zoberi practices at Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health.

Dr. Zoberi's NPI, 1710903034, was assigned on July 14, 2006. Dr. Zoberi graduated from Washington University School of Medicine in 1996. Dr. Zoberi holds Missouri license 110658.

Dr. Zoberi's primary practice is Barnes-Jewish Hospital, at One Barnes-Jewish Hospital Plaza, Saint Louis, MO 63110 in St. Louis City. The practice phone is (314) 747-3000. Dr. Zoberi also practices at Barnes-Jewish Hospital, 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110.

Dr. Zoberi's primary practice is Barnes-Jewish Hospital in Saint Louis, Missouri, part of BJC Health. Dr. Zoberi is also affiliated with Barnes-Jewish West County Hospital. The medical group on file is WashU Medicine Psychiatry. Dmand AI also links Dr. Zoberi to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zoberi practices, 6 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Zoberi's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Zoberi is licensed in Missouri.

CMS data shows 1,865 Medicare services from Dr. Zoberi across 19 procedure codes in 2024, for 224 Medicare patients. Medicare paid $117,080 for them.

CMS counts 224 Medicare patients who saw Dr. Zoberi in 2024. The largest group is 65 to 74, with 132 patients. 75% of them have cancer, and 64% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zoberi's median patient age at 70, with 94% women.

In 2024, Dr. Zoberi wrote 20 Medicare Part D claims for 14 patients. 80% of them were for generic drugs. CMS names the drug for 17 of them, across 1 drug with 11 or more claims each, at $1,430 in total drug cost. In 2022, CMS named 27 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Zoberi for performance year 2024, reported as part of a group. Dr. Zoberi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 50 papers to Dr. Zoberi, published from 2011 to 2025. 2019 was the busiest year, with 7. The most frequent topics are Breast Neoplasms, Radiotherapy Planning, Computer-Assisted and Radiotherapy Dosage. Dr. Zoberi has published most often in Brachytherapy. Dr. Zoberi's most frequent co-authors are Julie A. Margenthaler, MD, Amy Elizabeth Cyr, MD and Prashant S. Gabani, MD.

Dmand AI links Dr. Zoberi to 9 clinical trials. 5 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Brain Neoplasms. Washington University School of Medicine sponsors the most, 6.

CMS Open Payments shows 17 general payments to Dr. Zoberi from 7 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 68% of the total. Viewray Technologies Inc paid the most, $3,871.

Dr. Zoberi graduated from Washington University School of Medicine in 1996.